Pulmonary Medicine

Growing prevalence of COPD provides need for drugs

Published in Health and Medicine Week, September 16th, 2002

The growing prevalence of chronic obstructive pulmonary disease (COPD) and the high, unmet medical need for drugs that can stop or reverse the progression of the disease provide great opportunities for pharmaceuticals companies.

New analysis from Frost & Sullivan, "U.S. Chronic Obstructive Pulmonary Disease Therapies Markets", reveals that this industry generated revenues totaling $1.89 billion in 2001. Total market revenues could reach $2.97 billion in 2008.

The growing acceptance of long-acting beta2 agonist therapies is the major driver behind growth in market revenues. According to Frost & Sullivan Industry Analyst T. O'Connell, "The efficacy...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2002-09-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry